Florida Revives Bombshell Gender-Care Fight

A wooden gavel resting on a courtroom table with a scale of justice in the background

A powerful appeals court has just let Florida revive its challenge to pediatric groups that promote gender-transition treatments for children, reopening a major legal fight over truth, science, and free speech.

Story Snapshot

Florida’s lawsuit against top pediatric and medical groups over gender-transition care for minors is back on track after an appeals court stay.
The case claims these groups misled families by calling puberty blockers fully reversible and “evidence-based,” and by downplaying risks.
A federal judge earlier blasted Florida’s suit as “bad faith” and aimed at silencing speech, but that ruling is now paused.
The clash tests how far states can go to challenge medical elites while still respecting the First Amendment and consumer protection laws.

Appeals court reopens Florida’s challenge to pediatric elites

A United States appeals court in Chicago has cleared the way for Florida Attorney General James Uthmeier to again press his claims against the American Academy of Pediatrics and two allied medical groups over gender-transition treatment for minors. The full Seventh Circuit Court of Appeals voted to stay a June ruling that had blocked Florida’s lawsuit, meaning the state case in Florida can move forward while the federal free-speech fight continues. This is a key turning point in a legal battle watched across the country.

Florida’s original lawsuit, filed in December 2025, targets the American Academy of Pediatrics, the World Professional Association for Transgender Health, and the Endocrine Society. The complaint says these organizations misled the public about the safety, reversibility, and supposed evidence base for gender-affirming medical interventions on children, including puberty blockers and cross-sex hormones. Florida brings claims under its Deceptive and Unfair Trade Practices Act and its Racketeer Influence and Corrupt Organizations law, signaling that the state views this not just as bad science but as alleged organized misconduct.

What Florida says the medical groups got wrong

Florida’s complaint focuses on several specific claims made by these medical organizations, especially in the American Academy of Pediatrics’ policy statements on transgender and “gender-diverse” youth. The state says the groups falsely told the public that sex interventions reduce gender dysphoria and suicidality, that puberty blockers are fully reversible, and that their guidelines are solidly “evidence-based.” The complaint also accuses them of pushing these messages to grow memberships and business for doctors and clinics that provide such treatments, suggesting a financial motive behind the advocacy.

The lawsuit points back to a 2018 American Academy of Pediatrics policy statement, reaffirmed in 2023, which endorses comprehensive support and medical interventions for transgender-identifying children and teens. Florida argues that this and related guidance rely on weak or cherry-picked data while ignoring risks to bone health, fertility, sexual function, and long-term mental health. The complaint paints a picture of medical leaders using strong moral language to sell a controversial model of care as settled science, even though key questions about long-term outcomes and reversibility remain contested.

Free speech, “bad faith,” and the federal court clash

The American Academy of Pediatrics did not just defend itself in Florida; it went on offense by suing Uthmeier in federal court in Chicago, arguing that his state lawsuit was retaliation for the group’s advocacy and violated its First Amendment rights. United States District Judge Matthew Kennelly granted the Academy a preliminary injunction in June, stopping Florida from pursuing the state case for the moment and finding that the complaint showed “objective weakness” and signs of bad faith. He pointed to serious misrepresentations of the Academy’s policy positions and to inflammatory social media posts by Uthmeier as evidence that the motive was to punish speech, not protect consumers.

Judge Kennelly stressed that the Academy’s 2018 policy, reaffirmed in 2023, has long been publicly available, undercutting any claim that the group was hiding its views. From his perspective, the dispute was not about secret business practices but about whether a professional association may speak out in favor of gender-affirming care without facing crushing litigation from a state official. His ruling gave major media outlets reason to frame Florida’s suit as a political attack dressed up as a trade-practices case, and several outlets described the lawsuit as an effort to silence advocates for transgender youth.

Appeals court narrows the First Amendment shield

The Seventh Circuit’s recent decision does not fully decide who is right, but it does limit how far Judge Kennelly’s injunction can go, at least for now. By staying his order, the appeals court signaled that Florida’s consumer-protection and racketeering claims are not so clearly unconstitutional that they must be frozen while the Academy’s free-speech case plays out. The state lawsuit in Florida therefore remains pending, with a trial schedule still to be set, and Florida can press discovery and other steps in its effort to test the medical groups’ claims in court.

Major development as appeals court allows Florida's lawsuit against AAP over gender-transition guidance to move forward. This case could have significant implications for medical organizations' liability when… #Florida #MedicalLiability #AAP #Healthcare https://t.co/OJkZ71AL44

— @GlobalRightWatch (@AutonomusRepost) July 11, 2026

This tug-of-war between state power and free speech lands in the middle of a wider national struggle over gender-transition medicine for minors. In recent years, many states have passed laws limiting or criminalizing youth gender-affirming procedures, while leading medical organizations continue to endorse these interventions as necessary care. Florida’s case stands out because it uses tools usually aimed at consumer fraud and racketeering to challenge medical guidelines themselves. The outcome could shape how much accountability, if any, medical elites face when their policy pushes collide with growing public concern over the long-term impact on children.